

glycosylated human or altered antibody wherein said antibody is effective in treating said disorder, the improvement [which comprises administering a therapeutically effective amount of a CHO glycosylated form of the antibody] wherein the Fc region of said antibody has CHO glycosylation.

REMARKS

The new title set forth above is proposed to more specifically describe the invention claimed in the present application. The amendment to claim 27 is made to correct an obvious typographical error and to more clearly define the subject matter of the invention. No new matter is introduced into the application by these amendments.

Applicant has amended page 14 of the specification so that the reference to Figure 1 has been changed to Figures 1(a) and 1(b) to correspond to changes that will be made to the first sheet of drawing upon an indication of allowable subject matter and the submission of formal drawings. Enclosed herewith is a copy of that drawing sheet showing in red the proposed change.

Claim 1 has been rejected under 35 U.S.C. § 101 as claiming the same invention as that of claim 1 of co-pending application Serial Number 08/335,401. This rejection was asserted to be a provisional double patenting rejection as the conflicting claims have not been patented. Applicant respectfully submits that this rejection has been obviated by the cancellation of claim 1 from this application.